Comparing two drug combinations before breast cancer surgery
Treatments studied
Part of Cancer, Skin clinical trials.
This study is comparing two different drug combinations given before breast cancer surgery. The goal is to see which one shrinks tumors more effectively. This type of treatment is called 'neoadjuvant' therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 70 years old.
- You have been diagnosed with stage II or III breast cancer that is HER2-positive (a type of protein that helps cancer grow).
- Your tumor is at least 2 cm in size.
- You have not had previous cancer treatment, like chemotherapy or radiation.
- You have no major heart problems.
- You are able to care for yourself and are not bedridden.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, trastuzumab deruxtecan (SHR-A1811) and pertuzumab, given before surgery to shrink HER2-positive breast cancer. It is for women with stage II or III breast cancer who have not yet had treatment and are in good overall health.
This trial tests a treatment given before breast surgery to shrink breast cancer and improve outcomes based on your tumor type. Your eligibility depends on tumor size/stage, hormone and HER2 markers, and overall health checks.
This trial tests two different combinations of chemotherapy and targeted therapy given before surgery for HER2-positive breast cancer. The goal is to see which combination works better at shrinking the tumor.
This trial tests a combination of targeted therapies and chemotherapy given before surgery for women with a specific type of breast cancer that is both ER-positive and HER2-positive. The goal is to see if this treatment can shrink tumors and improve outcomes.
This trial compares two combination treatment plans given before breast surgery (neoadjuvant therapy) for ER-positive and HER2-positive stage II–III breast cancer. It aims to see which plan works better to shrink the tumor and improve outcomes.
This trial tests a combination of targeted therapies and chemotherapy given before surgery for HER2-positive breast cancer. It aims to see if this approach helps shrink tumors and improve outcomes.
Hear when a new Breast Cancer Early Stage Breast Cancer (Stage 1-3) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.